The MUST Research Group, which successfully completed the Multicenter Uveitis Steroid Treatment (MUST) Trial is conducting two new trials, the Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial and the Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy (MERIT) Trial. Both are funded by the National Eye Institute. POINT will compare the relative efficacy of three common approaches for the regional treatment of uveitic macular edema, periocular and intravitreal triamcinolone acetonide, and the dexamethasone intravitreal implant. MERIT will evaluate the relative efficacy of intravitreal ranibizumab and intravitreal methotrexate and the dexamethasone intravitreal implant for the treatment of uveitic macular edema persisting after intravitreal triamcinolone acetonide. The POINT Trial will be initiated in Spring 2015 in clinical centers that are currently following participants in the MUST Trial Follow-up Study and to have new clinical centers selected and preparing for start-up by the time of our Research Group meeting in June 2015. The MERIT Trial will begin approximately 12 months after the start of POINT; the trials will run concurrently until POINT is completed.
Those interested in being a clinical center for POINT and MERIT should visit the Clinic Applications site or read the attached document to learn more.
